Henry Ford Hospital is teaming up with Rosetta Genomics to develop microRNA-based diagnostics and prognostics for brain cancer.
Excerpt:
"The goal of our collaborations with the leading cancer research
centers is to seek new indications for our microRNA-based diagnostics,"
said Amir Avniel, President and CEO of Rosetta Genomics. "Together with
Henry Ford Hopsital's leading brain cancer researchers, we believe we
will be able to leverage the potential microRNAs hold as biomarkers to
develop diagnostic and prognostic tools for this difficult disease."
Read the entire article
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.